✉news HealthMedicine first seen 12 h ago, last 8 h ago, peak #33
Prime Medicine Downgraded to Sell by Wall Street Zen
Original: Prime Medicine (NASDAQ:PRME) Cut to "Sell" at Wall Street Zen
Prime Medicine, the NASDAQ-listed gene editing company, was downgraded to a "Sell" rating by research firm Wall Street Zen. The move affects how investors view the stock, which trades under the ticker PRME. No further details on the rationale for the downgrade were provided in initial coverage.
Why now: Investors are reacting to a fresh analyst downgrade of a biotech stock
Prime MedicineWall Street ZenNASDAQ
Evidence
API: https://socialmediatrends-api.osmike.com/v1/trends/830341